Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 1609575, 16 pages
https://doi.org/10.1155/2017/1609575
Review Article

New Insights into the Epigenetics of Hepatocellular Carcinoma

1Centre for Applied Molecular Biology, 87 West Canal Bank Road Thokar Niaz Baig, University of the Punjab, Lahore, Pakistan
2Hazara University, Mansehra, Pakistan

Correspondence should be addressed to Amjad Ali; kp.ude.up@bmac.dajma

Received 26 August 2016; Accepted 17 January 2017; Published 19 March 2017

Academic Editor: Mario Scartozzi

Copyright © 2017 Braira Wahid et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. Z. Herceg and A. Paliwal, “Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome,” Mutation Research/Reviews in Mutation Research, vol. 727, no. 3, pp. 55–61, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Ma, M.-S. Chua, O. Andrisani, and S. So, “Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives,” World Journal of Gastroenterology, vol. 20, no. 2, pp. 333–345, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Zhang, “Detection of epigenetic aberrations in the development of hepatocellular carcinoma,” in Cancer Epigenetics: Risk Assessment, Diagnosis, Treatment, and Prognosis, pp. 709–731, Springer, 2015. View at Google Scholar
  5. I. Hernando-Herraez, R. Garcia-Perez, A. J. Sharp, and T. Marques-Bonet, “DNA methylation: insights into human evolution,” PLoS Genetics, vol. 11, no. 12, Article ID e1005661, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. E. L. Sceusi, D. S. Loose, and C. J. Wray, “Clinical implications of DNA methylation in hepatocellular carcinoma,” HPB, vol. 13, no. 6, pp. 369–376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Weber, I. Hellmann, M. B. Stadler et al., “Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome,” Nature Genetics, vol. 39, no. 4, pp. 457–466, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Esteller, P. G. Corn, S. B. Baylin, and J. G. Herman, “A gene hypermethylation profile of human cancer,” Cancer Research, vol. 61, no. 8, pp. 3225–3229, 2001. View at Google Scholar · View at Scopus
  9. Y.-F. He, B.-Z. Li, Z. Li et al., “Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA,” Science, vol. 333, no. 6047, pp. 1303–1307, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. M. C. Haffner, A. Chaux, A. K. Meeker et al., “Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers,” Oncotarget, vol. 2, no. 8, pp. 627–637, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S.-G. Jin, Y. Jiang, R. Qiu et al., “5-hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations,” Cancer Research, vol. 71, no. 24, pp. 7360–7365, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M.-A. Song, M. Tiirikainen, S. Kwee, G. Okimoto, H. Yu, and L. L. Wong, “Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma,” PLoS ONE, vol. 8, no. 2, Article ID e55761, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. M.-P. Lambert, P.-B. Ancey, D. D. Esposti et al., “Aberrant DNA methylation of imprinted loci in hepatocellular carcinoma and after in vitro exposure to common risk factors,” Clinical Epigenetics, vol. 7, no. 1, p. 1, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Etoh, Y. Kanai, S. Ushijima et al., “Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers,” The American Journal of Pathology, vol. 164, no. 2, pp. 689–699, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. DNMT1 DNA methyltransferase 1 [Homo sapiens (human)].
  16. K. Liu, Y. Zhang, C. Zhang et al., “Methylation of S100A8 is a promising diagnosis and prognostic marker in hepatocellular carcinoma,” Oncotarget, vol. 7, no. 35, pp. 56798–56810, 2016. View at Publisher · View at Google Scholar
  17. H. G. Lee, H. Kim, T. Son et al., “Regulation of HK2 expression through alterations in CpG methylation of the HK2 promoter during progression of hepatocellular carcinoma,” Oncotarget, vol. 7, no. 27, pp. 41798–41810, 2016. View at Publisher · View at Google Scholar
  18. W.-R. Liu, Y.-H. Shi, Y.-F. Peng, and J. Fan, “Epigenetics of hepatocellular carcinoma: a new horizon,” Chinese Medical Journal, vol. 125, no. 13, pp. 2349–2360, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Nishida and A. Goe, “Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review,” Current Genomics, vol. 12, no. 2, pp. 130–137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. B. Baylin, “DNA methylation and gene silencing in cancer,” Nature Clinical Practice Oncology, vol. 2, no. 1, pp. S4–S11, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. Z. Herceg, “Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors,” Mutagenesis, vol. 22, no. 2, pp. 91–103, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Sawan, T. Vaissière, R. Murr, and Z. Herceg, “Epigenetic drivers and genetic passengers on the road to cancer,” Mutation Research—Fundamental and Molecular Mechanisms of Mutagenesis, vol. 642, no. 1-2, pp. 1–13, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. M.-P. Lambert, A. Paliwal, T. Vaissière et al., “Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake,” Journal of Hepatology, vol. 54, no. 4, pp. 705–715, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. F. H. T. Duong, V. Christen, S. Lin, and M. H. Heim, “Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair,” Hepatology, vol. 51, no. 3, pp. 741–751, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. M. R. Higgs, H. Lerat, and J.-M. Pawlotsky, “Downregulation of Gadd45β expression by hepatitis C virus leads to defective cell cycle arrest,” Cancer Research, vol. 70, no. 12, pp. 4901–4911, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Hernandez-Vargas, M.-P. Lambert, F. Le Calvez-Kelm et al., “Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors,” PLoS ONE, vol. 5, no. 3, Article ID e9749, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Ye, R. Tao, Q. Cao et al., “Whole-genome DNA methylation and hydroxymethylation profiling for HBV-related hepatocellular carcinoma,” Age (Years), vol. 41, no. 53, p. 40, 2016. View at Google Scholar
  28. X. Tang, L. Ge, Z. Chen et al., “Methylation of the constitutive androstane receptor is involved in the suppression of CYP2C19 in hepatitis B Virus-associated hepatocellular carcinoma,” Drug Metabolism and Disposition, vol. 44, no. 10, pp. 1643–1652, 2016. View at Publisher · View at Google Scholar
  29. Y.-L. Shih, C.-C. Kuo, M.-D. Yan, Y.-W. Lin, C.-B. Hsieh, and T.-Y. Hsieh, “Quantitative methylation analysis reveals distinct association between PAX6 methylation and clinical characteristics with different viral infections in hepatocellular carcinoma,” Clinical Epigenetics, vol. 8, no. 1, article 41, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Shen, S. Wang, Y.-J. Zhang et al., “Genome-wide DNA methylation profiles in hepatocellular carcinoma,” Hepatology, vol. 55, no. 6, pp. 1799–1808, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Nishida, M. Kudo, T. Nagasaka, I. Ikai, and A. Goel, “Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma,” Hepatology, vol. 56, no. 3, pp. 994–1003, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Revill, T. Wang, A. Lachenmayer et al., “Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma,” Gastroenterology, vol. 145, no. 6, pp. 1424.e25–1435.e25, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. S. L. Anwar and U. Lehmann, “DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 20, no. 24, pp. 7894–7913, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Liu, H. Dong, K. Robertson, and C. Liu, “DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma,” The American Journal of Pathology, vol. 178, no. 2, pp. 652–661, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. I. Tischoff, A. Markwarth, H. Witzigmann et al., “Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors,” International Journal of Cancer, vol. 115, no. 5, pp. 684–689, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Zhang, X. Guo, G. Jiang et al., “CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma,” International Journal of Cancer, vol. 123, no. 5, pp. 998–1004, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. M. L. Tomasi, T. W. H. Li, M. Li, J. M. Mato, and S. C. Lu, “Inhibition of human methionine adenosyltransferase 1A transcription by coding region methylation,” Journal of Cellular Physiology, vol. 227, no. 4, pp. 1583–1591, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. O. Warburg, F. Wind, and F. Neglers, “The metabolism of tumours,” in Metabolism of Tumours, pp. 254–270, Constable & Co, London, UK, 1930. View at Google Scholar
  39. M. Rong, G. Chen, and Y. Dang, “Increased MiR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro,” BMC Cancer, vol. 13, no. 1, article 21, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Li, L. Fang, W. Yu, and Y. Wang, “MicroRNA-125b suppresses the migration and invasion of hepatocellular carcinoma cells by targeting transcriptional coactivator with PDZ-binding motif,” Oncology Letters, vol. 9, no. 4, pp. 1971–1975, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. L.-L. Zhang, Y.-J. Guo, C.-N. Zhao, and J.-Y. Gao, “Effects and mechanism of miR-214 on hepatocellular carcinoma,” Asian Pacific Journal of Tropical Medicine, vol. 8, no. 5, pp. 392–398, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Xie, J. Liu, L. Zhu et al., “A potentially functional polymorphism in the promoter region of let-7 family is associated with survival of hepatocellular carcinoma,” Cancer Epidemiology, vol. 37, no. 6, pp. 998–1002, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. X. Yang, L. Liang, X.-F. Zhang et al., “MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway,” Hepatology, vol. 58, no. 1, pp. 158–170, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Nassirpour, P. P. Mehta, and M.-J. Yin, “miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3,” PLoS ONE, vol. 8, no. 11, Article ID e79655, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. C. J.-F. Lin, H.-Y. Gong, H.-C. Tseng, W.-L. Wang, and J.-L. Wu, “miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines,” Biochemical and Biophysical Research Communications, vol. 375, no. 3, pp. 315–320, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. T.-H. Wang, C.-T. Yeh, J.-Y. Ho, K.-F. Ng, and T.-C. Chen, “OncomiR miR-96 and miR-182 promote cell proliferation and invasion through targeting ephrinA5 in hepatocellular carcinoma,” Molecular Carcinogenesis, vol. 55, no. 4, pp. 366–375, 2016. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Cao, J. Li, Y. Zhao et al., “miR-101 inhibiting cell proliferation, migration and invasion in hepatocellular carcinoma through downregulating girdin,” Molecules and Cells, vol. 39, no. 2, pp. 96–102, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Ruan, X. He, J. Yu, and Z. Hang, “MicroRNA-186 targets yes-associated protein 1 to inhibit hippo signaling and tumorigenesis in hepatocellular carcinoma,” Oncology Letters, vol. 11, no. 4, pp. 2941–2945, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Parpart, S. Roessler, F. Dong et al., “Modulation of miR-29 expression by alpha-fetoprotein is linked to the hepatocellular carcinoma epigenome,” Hepatology, vol. 60, no. 3, pp. 872–883, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Zhao and W. Wang, “miR-125b suppresses the proliferation of hepatocellular carcinoma cells by targeting Sirtuin7,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 10, pp. 18469–18475, 2015. View at Google Scholar · View at Scopus
  51. Z. Liu, C. Dou, B. Yao et al., “Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma,” Oncotarget, vol. 7, no. 24, pp. 36909–36923, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Kelong, Y. He, H. Zhang et al., “DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression,” Journal of Biological Chemistry, vol. 287, no. 8, pp. 5639–5649, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. Z. Tian, H. Jiang, Y. Liu et al., “MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1,” Experimental Cell Research, vol. 343, no. 2, pp. 135–147, 2016. View at Publisher · View at Google Scholar · View at Scopus
  54. Z. Luo, C. Feng, P. Hu et al., “Serum microRNA-199a/b-3p as a predictive biomarker for treatment response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization,” OncoTargets and Therapy, vol. 9, pp. 2667–2674, 2016. View at Publisher · View at Google Scholar · View at Scopus
  55. Q. Shen, V. R. Cicinnati, X. Zhang et al., “Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion,” Molecular Cancer, vol. 9, no. 1, article 227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Tang, B. Lei, G. Qi et al., “MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression,” Journal of Experimental and Clinical Cancer Research, vol. 35, no. 1, article 93, 2016. View at Publisher · View at Google Scholar · View at Scopus
  57. Y.-F. Yang, F. Wang, J.-J. Xiao et al., “MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27,” International Journal of Clinical and Experimental Medicine, vol. 7, no. 4, pp. 893–902, 2014. View at Google Scholar · View at Scopus
  58. G. Xu, Y. Zhang, J. Wei et al., “MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3,” BMC Cancer, vol. 13, no. 1, article 469, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Liu, K. Liu, W. Zhang et al., “MiR-449a inhibits proliferation and invasion by regulating ADAM10 in hepatocellular carcinoma,” American Journal of Translational Research, vol. 8, no. 6, pp. 2609–2619, 2016. View at Google Scholar · View at Scopus
  60. C. C.-L. Wong, C. Wong, E. K. Tung et al., “The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating rho-kinase 2,” Gastroenterology, vol. 140, no. 1, pp. 322–331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. Q. Bi, S. Tang, L. Xia et al., “Ectopic expression of miR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF,” PLoS ONE, vol. 7, no. 6, Article ID e40169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Tan, L. Wu, J. Tan et al., “MIR-1180 promotes apoptotic resistance to human hepatocellular carcinoma via activation of NF-κB signaling pathway,” Scientific Reports, vol. 6, article 22328, 2016. View at Publisher · View at Google Scholar · View at Scopus
  63. L. Zhang, F. Yang, J.-H. Yuan et al., “Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma,” Carcinogenesis, vol. 34, no. 3, pp. 577–586, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Tu, G. Wei, Q. Cai et al., “MicroRNA-212 inhibits hepatocellular carcinoma cell proliferation and induces apoptosis by targeting FOXA1,” OncoTargets and Therapy, vol. 8, pp. 2227–2235, 2015. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Dou, Y. Wang, C. Li et al., “MicroRNA-212 suppresses tumor growth of human hepatocellular carcinoma by targeting FOXA1,” Oncotarget, vol. 6, no. 15, pp. 13216–13228, 2015. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Zhang, Z. Yu, Y. Xian, and X. Lin, “microRNA-497 inhibits cell proliferation and induces apoptosis by targeting YAP1 in human hepatocellular carcinoma,” FEBS Open Bio, vol. 6, no. 2, pp. 155–164, 2016. View at Publisher · View at Google Scholar · View at Scopus
  67. F. Fornari, M. Milazzo, P. Chieco et al., “In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2,” Journal of Pathology, vol. 227, no. 3, pp. 275–285, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. Y. Li, W. Tan, T. W. L. Neo et al., “Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma,” Cancer Science, vol. 100, no. 7, pp. 1234–1242, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. L. Yang, X. Zhang, H. Li, and J. Liu, “The long noncoding RNA HOTAIR activates autophagy by upregulating ATG3 and ATG7 in hepatocellular carcinoma,” Molecular BioSystems, vol. 12, no. 8, pp. 2605–2612, 2016. View at Publisher · View at Google Scholar · View at Scopus
  70. J.-Z. Gao, J. Li, J.-L. Du, and X.-L. Li, “Long non-coding RNA HOTAIR is a marker for hepatocellular carcinoma progression and tumor recurrence,” Oncology Letters, vol. 11, no. 3, pp. 1791–1798, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Deng, S.-B. Yang, F.-F. Xu, and J.-H. Zhang, “Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 sponge,” Journal of Experimental and Clinical Cancer Research, vol. 34, no. 1, article 18, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Li, H. Xu, Y. Yu et al., “LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway,” Oncotarget, vol. 7, no. 27, pp. 42431–42446, 2016. View at Publisher · View at Google Scholar
  73. J. Wu, Y. Qin, B. Li, W.-Z. He, and Z.-L. Sun, “Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGF2 and H19 in human hepatocellular carcinoma,” Genomics, vol. 91, no. 5, pp. 443–450, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Quagliata, M. S. Matter, S. Piscuoglio et al., “Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients,” Hepatology, vol. 59, no. 3, pp. 911–923, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. F. H. C. Tsang, S. L. K. Au, L. Wei et al., “Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive miR-125b,” Liver International, vol. 35, no. 5, pp. 1597–1606, 2015. View at Publisher · View at Google Scholar · View at Scopus
  76. T. Zhou and Y. Gao, “Increased expression of LncRNA BANCR and its prognostic significance in human hepatocellular carcinoma,” World Journal of Surgical Oncology, vol. 14, no. 1, article 8, 2016. View at Publisher · View at Google Scholar · View at Scopus
  77. M.-C. Lai, Z. Yang, L. Zhou et al., “Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation,” Medical Oncology, vol. 29, no. 3, pp. 1810–1816, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. F. Yang, L. Zhang, X.-S. Huo et al., “Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans,” Hepatology, vol. 54, no. 5, pp. 1679–1689, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. C.-L. Chen, Y.-W. Tseng, J.-C. Wu et al., “Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and MicroRNA regulation,” Biomaterials, vol. 44, pp. 71–81, 2015. View at Publisher · View at Google Scholar · View at Scopus
  80. D. Zhang, C. Cao, L. Liu, and D. Wu, “Up-regulation of LncRNA SNHG20 predicts poor prognosis in hepatocellular carcinoma,” Journal of Cancer, vol. 7, no. 5, pp. 608–617, 2016. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Zhuo, J. Tang, Z. Lin et al., “The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma,” Molecular Carcinogenesis, vol. 55, no. 2, pp. 209–219, 2016. View at Publisher · View at Google Scholar · View at Scopus
  82. T. Kogure, I. K. Yan, W.-L. Lin, and T. Patel, “Extracellular vesicle-mediated transfer of a novel long noncoding RNA TUC339: a mechanism of intercellular signaling in human hepatocellular cancer,” Genes and Cancer, vol. 4, no. 7-8, pp. 261–272, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. C. Braconi, N. Valeri, T. Kogure et al., “Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 2, pp. 786–791, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Takahashi, I. K. Yan, H. Haga, and T. Patel, “Modulation of hypoxia-signaling pathways by extracellular linc-RoR,” Journal of Cell Science, vol. 127, no. 7, pp. 1585–1594, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. K. Takahashi, I. K. Yan, T. Kogure, H. Haga, and T. Patel, “Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer,” FEBS Open Bio, vol. 4, no. 1, pp. 458–467, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. S.-X. Yuan, F. Yang, Y. Yang et al., “Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence-free survival after hepatectomy,” Hepatology, vol. 56, no. 6, pp. 2231–2241, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. J.-H. Yuan, F. Yang, F. Wang et al., “A Long Noncoding RNA Activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma,” Cancer Cell, vol. 25, no. 5, pp. 666–681, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. M.-D. Huang, W.-M. Chen, F.-Z. Qi et al., “Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2,” Molecular Cancer, vol. 14, no. 1, article 165, 2015. View at Publisher · View at Google Scholar · View at Scopus
  89. W.-H. Xu, J.-B. Zhang, Z. Dang et al., “Long non-coding RNA URHC regulates cell proliferation and apoptosis via ZAK through the ERK/MAPK signaling pathway in hepatocellular carcinoma,” International Journal of Biological Sciences, vol. 10, no. 7, pp. 664–676, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. F. Liu, J.-H. Yuan, J.-F. Huang et al., “Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a,” Oncogene, vol. 35, no. 41, pp. 5422–5434, 2016. View at Publisher · View at Google Scholar · View at Scopus
  91. C. Ding, Z. Yang, Z. Lv et al., “Long non-coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients,” Oncology Letters, vol. 9, no. 2, pp. 955–963, 2015. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Jia, L. Jiang, Y.-D. Wang, J.-Z. Huang, M. Yu, and H.-Z. Xue, “LincRNA‐p21 inhibits invasion and metastasis of hepatocellular carcinoma through Notch signaling induced epithelial‐mesenchymal transition,” Hepatology Research, vol. 46, no. 11, pp. 1137–1144, 2016. View at Google Scholar
  93. F. Wang, H.-Q. Ying, B.-S. He et al., “Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway,” Oncotarget, vol. 6, no. 10, pp. 7899–7917, 2015. View at Publisher · View at Google Scholar · View at Scopus
  94. W. Yu, Y. Qiao, X. Tang et al., “Tumor suppressor long non-coding RNA, MT1DP is negatively regulated by YAP and Runx2 to inhibit FoxA1 in liver cancer cells,” Cellular Signalling, vol. 26, no. 12, pp. 2961–2968, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. C. Cao, J. Sun, D. Zhang et al., “The long intergenic noncoding RNA UFC1, a target of microRNA 34a, interacts with the mRNA stabilizing protein HuR to increase levels of β-catenin in HCC cells,” Gastroenterology, vol. 148, no. 2, pp. 415–426, 2015. View at Publisher · View at Google Scholar · View at Scopus
  96. H. Zheng, S. Yang, Y. Yang et al., “Epigenetically silenced long noncoding-SRHC promotes proliferation of hepatocellular carcinoma,” Journal of Cancer Research and Clinical Oncology, vol. 141, no. 7, pp. 1195–1203, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. S.-X. Yuan, Q.-F. Tao, J. Wang et al., “Antisense long non-coding RNA PCNA-AS1 promotes tumor growth by regulating proliferating cell nuclear antigen in hepatocellular carcinoma,” Cancer Letters, vol. 349, no. 1, pp. 87–94, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. J.-F. Huang, Y.-J. Guo, C.-X. Zhao et al., “Hepatitis B virus X protein (HBx)-related long noncoding RNA (lncRNA) down-regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin,” Hepatology, vol. 57, no. 5, pp. 1882–1892, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. W. P. Tsang, T. W. L. Wong, A. H. H. Cheung, C. N. N. Co, and T. T. Kwok, “Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR,” RNA, vol. 13, no. 6, pp. 890–898, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. D. Carlisi, M. Lauricella, A. D'Anneo et al., “The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation,” European Journal of Cancer, vol. 45, no. 13, pp. 2425–2438, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. W. Yeo, H. C. Chung, S. L. Chan et al., “Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the mayo phase II consortium and the cancer therapeutics research group,” Journal of Clinical Oncology, vol. 30, no. 27, pp. 3361–3367, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. B. B. Y. Ma, F. Sung, Q. Tao et al., “The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines,” Investigational New Drugs, vol. 28, no. 2, pp. 107–114, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. S.-F. Tao, C.-S. Zhang, X.-L. Guo et al., “Anti-tumor effect of 5-aza-2′-deoxycytidine by inhibiting telomerase activity in hepatocellular carcinoma cells,” World Journal of Gastroenterology, vol. 18, no. 19, pp. 2334–2343, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. K. Nakamura, K. Aizawa, K. Nakabayashi et al., “DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis,” PLoS ONE, vol. 8, no. 1, Article ID e54036, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. J. B. Andersen, V. M. Factor, J. U. Marquardt et al., “An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer,” Science Translational Medicine, vol. 2, no. 54, p. 54ra77, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. A. Lachenmayer, S. Toffanin, L. Cabellos et al., “Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib,” Journal of Hepatology, vol. 56, no. 6, pp. 1343–1350, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. P. A. Jones and S. B. Baylin, “The fundamental role of epigenetic events in cancer,” Nature Reviews Genetics, vol. 3, no. 6, pp. 415–428, 2002. View at Google Scholar · View at Scopus
  108. H. van Attikum and S. M. Gasser, “Crosstalk between histone modifications during the DNA damage response,” Trends in Cell Biology, vol. 19, no. 5, pp. 207–217, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. C. T. Nguyen, D. J. Weisenberger, M. Velicescu et al., “Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine,” Cancer Research, vol. 62, no. 22, pp. 6456–6461, 2002. View at Google Scholar · View at Scopus
  110. H. Chen, T. Zhang, Y. Sheng et al., “Methylation profiling of multiple tumor suppressor genes in hepatocellular carcinoma and the epigenetic mechanism of 3OST2 regulation,” Journal of Cancer, vol. 6, no. 8, pp. 740–749, 2015. View at Publisher · View at Google Scholar · View at Scopus
  111. R. Cao and Y. Zhang, “The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3,” Current Opinion in Genetics and Development, vol. 14, no. 2, pp. 155–164, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. A. P. Bracken, D. Pasini, M. Capra, E. Prosperini, E. Colli, and K. Helin, “EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer,” The EMBO Journal, vol. 22, no. 20, pp. 5323–5335, 2003. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Lachner, R. J. O'Sullivan, and T. Jenuwein, “An epigenetic road map for histone lysine methylation,” Journal of Cell Science, vol. 116, no. 11, pp. 2117–2124, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. S. Varambally, S. M. Dhanasekaran, M. Zhou et al., “The polycomb group protein EZH2 is involved in progression of prostate cancer,” Nature, vol. 419, no. 6907, pp. 624–629, 2002. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Bhattacharya, D. Reddy, A. Ingle, B. Khade, and S. Gupta, “Brief Communication: Featured Article: Histone H2A mono-ubiquitination and cellular transformation are inversely related in N-nitrosodiethylamine-induced hepatocellular carcinoma,” Experimental biology and Medicine (Maywood, N.J.), vol. 241, no. 16, pp. 1739–1744, 2016. View at Publisher · View at Google Scholar
  116. C. Magerl, J. Ellinger, T. Braunschweig et al., “H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1,” Human Pathology, vol. 41, no. 2, pp. 181–189, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. J. K. Shon, B. H. Shon, I. Y. Park et al., “Hepatitis B virus-X protein recruits histone deacetylase 1 to repress insulin-like growth factor binding protein 3 transcription,” Virus Research, vol. 139, no. 1, pp. 14–21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. K. Schulze, S. Imbeaud, E. Letouzé et al., “Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets,” Nature Genetics, vol. 47, no. 5, pp. 505–511, 2015. View at Publisher · View at Google Scholar · View at Scopus
  119. W.-K. Sung, H. Zheng, S. Li et al., “Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma,” Nature Genetics, vol. 44, no. 7, pp. 765–769, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. C. He, J. Xu, J. Zhang et al., “High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma,” Human Pathology, vol. 43, no. 9, pp. 1425–1435, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. C. M. Wong, L. Wei, C. T. Law et al., “Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis,” Hepatology, vol. 63, no. 2, pp. 474–487, 2016. View at Google Scholar
  122. X. Zhang, J. Wu, J. Choiniere et al., “Arsenic silences hepatic PDK4 expression through activation of histone H3K9 methylatransferase G9a,” Toxicology and Applied Pharmacology, vol. 304, pp. 42–47, 2016. View at Publisher · View at Google Scholar · View at Scopus
  123. T. Longerich, “Dysregulation of the epigenetic regulator SETDB1 in liver carcinogenesis—more than one way to skin a cat,” Chinese Clinical Oncology, vol. 5, no. 6, pp. 72–72, 2016. View at Publisher · View at Google Scholar
  124. J. Zhu, “DNA methylation and hepatocellular carcinoma,” Journal of Hepato-Biliary-Pancreatic Surgery, vol. 13, no. 4, pp. 265–273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  125. Y.-J. Liao, S.-P. Liu, C.-M. Lee et al., “Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular carcinoma: implications of the gender disparity in liver cancer susceptibility,” International Journal of Cancer, vol. 124, no. 4, pp. 816–826, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. A. Moeini, H. Cornellà, and A. Villanueva, “Emerging signaling pathways in hepatocellular carcinoma,” Liver Cancer, vol. 1, no. 2, pp. 83–93, 2012. View at Publisher · View at Google Scholar
  127. D. Huang, J. Fang, and G. Luo, “Roles of long noncoding RNAs in Hepatocellular Carcinoma,” Open Life Sciences, vol. 11, no. 1, pp. 91–97, 2016. View at Publisher · View at Google Scholar · View at Scopus
  128. K. J. Falkenberg and R. W. Johnstone, “Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders,” Nature Reviews Drug Discovery, vol. 13, no. 9, pp. 673–691, 2014. View at Publisher · View at Google Scholar · View at Scopus
  129. T. Rikimaru, A. Taketomi, Y.-I. Yamashita et al., “Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma,” Oncology, vol. 72, no. 1-2, pp. 69–74, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. C. Liu, L. Liu, J. Shan et al., “Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification,” Cancer Letters, vol. 339, no. 1, pp. 60–69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  131. S. Bhaskara, S. K. Knutson, G. Jiang et al., “Hdac3 is essential for the maintenance of chromatin structure and genome stability,” Cancer Cell, vol. 18, no. 5, pp. 436–447, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. E. Ceccacci and S. Minucci, “Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia,” British Journal of Cancer, vol. 114, no. 6, pp. 605–611, 2016. View at Publisher · View at Google Scholar · View at Scopus
  133. J. Huang, “Current progress in epigenetic research for hepatocarcinomagenesis,” Science in China, Series C: Life Sciences, vol. 52, no. 1, pp. 31–42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  134. D. Cougot, Y. Wu, S. Cairo et al., “The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription,” The Journal of Biological Chemistry, vol. 282, no. 7, pp. 4277–4287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. D.-L. Zheng, L. Zhang, N. Cheng et al., “Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A,” Journal of Hepatology, vol. 50, no. 2, pp. 377–387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. M. Pal-Bhadra, U. Bhadra, D. E. Jackson, L. Mamatha, P.-H. Park, and S. D. Shukla, “Distinct methylation patterns in histone H3 at Lys-4 and Lys-9 correlate with up- & down-regulation of genes by ethanol in hepatocytes,” Life Sciences, vol. 81, no. 12, pp. 979–987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  137. H. Yang, Y. Nie, Y. Li, and Y.-J. Y. Wan, “Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells,” Experimental Biology and Medicine, vol. 235, no. 1, pp. 32–39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  138. G. Zhu, T. Tao, D. Zhang et al., “O-GlcNAcylation of histone deacetylases 1 in hepatocellular carcinoma promotes cancer progression,” Glycobiology, vol. 26, no. 8, pp. 820–833, 2016. View at Publisher · View at Google Scholar
  139. B.-H. Wu, H. Chen, C.-M. Cai et al., “Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription of CDKN1A,” Oncotarget, vol. 7, no. 6, pp. 6847–6863, 2016. View at Publisher · View at Google Scholar · View at Scopus
  140. B. G. Wilson and C. W. M. Roberts, “SWI/SNF nucleosome remodellers and cancer,” Nature Reviews Cancer, vol. 11, no. 7, pp. 481–492, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. M. Endo, K. Yasui, Y. Zen et al., “Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma,” Liver International, vol. 33, no. 1, pp. 105–117, 2013. View at Publisher · View at Google Scholar · View at Scopus
  142. C. Guichard, G. Amaddeo, S. Imbeaud et al., “Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma,” Nature Genetics, vol. 44, no. 6, pp. 694–698, 2012. View at Publisher · View at Google Scholar · View at Scopus
  143. M. Li, H. Zhao, X. Zhang et al., “Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma,” Nature Genetics, vol. 43, no. 9, pp. 828–829, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. M. Liu, L. Chen, N.-F. Ma et al., “CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors,” Hepatology, vol. 63, no. 5, pp. 1544–1559, 2016. View at Publisher · View at Google Scholar · View at Scopus
  145. Z. Wang and X. Li, “The role of noncoding RNA in hepatocellular carcinoma,” Gland Surgery, vol. 2, no. 1, p. 25, 2013. View at Google Scholar
  146. J. George and T. Patel, “Noncoding RNA as therapeutic targets for hepatocellular carcinoma,” in Seminars in Liver Disease, Thieme Medical Publishers, Stuttgart, Germany, 2015. View at Google Scholar
  147. Z. Liu, J. Wang, Y. Mao, B. Zou, and X. Fan, “MicroRNA-101 suppresses migration and invasion via targeting vascular endothelial growth factor-C in hepatocellular carcinoma cells,” Oncology Letters, vol. 11, no. 1, pp. 433–438, 2016. View at Publisher · View at Google Scholar · View at Scopus
  148. Z. Najafi, M. Sharifi, and G. Javadi, “Degradation of miR-21 induces apoptosis and inhibits cell proliferation in human hepatocellular carcinoma,” Cancer Gene Therapy, vol. 22, no. 11, pp. 530–535, 2015. View at Publisher · View at Google Scholar · View at Scopus
  149. P. Wang, S. Chen, H. Fang et al., “miR-214/199a/199a cluster levels predict poor survival in hepatocellular carcinoma through interference with cell-cycle regulators,” Oncotarget, vol. 7, no. 1, pp. 929–945, 2016. View at Publisher · View at Google Scholar
  150. X. Q. Jia, H. Q. Cheng, X. Qian et al., “Lentivirus-mediated overexpression of microRNA-199a inhibits cell proliferation of human hepatocellular carcinoma,” Cell Biochemistry and Biophysics, vol. 62, no. 1, pp. 237–244, 2012. View at Publisher · View at Google Scholar · View at Scopus
  151. S. Zhu, C. M. Chen, Z. Y. Jiang et al., “MicroRNA-185 inhibits cell proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Six2,” European Review for Medical and Pharmacological Sciences, vol. 20, no. 9, pp. 1712–1719, 2016. View at Google Scholar
  152. X. Zhou, H.-Q. Zhu, C.-Q. Ma et al., “MiR-1180 promoted the proliferation of hepatocellular carcinoma cells by repressing TNIP2 expression,” Biomedicine & Pharmacotherapy, vol. 79, pp. 315–320, 2016. View at Publisher · View at Google Scholar · View at Scopus
  153. Y.-B. Zeng, X.-H. Liang, G.-X. Zhang et al., “miRNA-135a promotes hepatocellular carcinoma cell migration and invasion by targeting forkhead box O1,” Cancer Cell International, vol. 16, no. 1, article 63, 2016. View at Publisher · View at Google Scholar · View at Scopus
  154. Y. He, X.-M. Meng, C. Huang et al., “Long noncoding RNAs: novel insights into hepatocelluar carcinoma,” Cancer Letters, vol. 344, no. 1, pp. 20–27, 2014. View at Publisher · View at Google Scholar · View at Scopus
  155. Y. Gao, G. Chen, Y. Zeng et al., “Invasion and metastasis-related long noncoding RNA expression profiles in hepatocellular carcinoma,” Tumor Biology, vol. 36, no. 10, pp. 7409–7422, 2015. View at Publisher · View at Google Scholar · View at Scopus
  156. D. Ngo-Yin Fan, F. Ho-Ching Tsang, A. Hoi-Kam Tam et al., “Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b,” Hepatology, vol. 57, no. 2, pp. 637–647, 2013. View at Publisher · View at Google Scholar · View at Scopus
  157. W. Mah and C. G. Lee, “DNA methylation: potential biomarker in Hepatocellular Carcinoma,” Biomarker Research, vol. 2, no. 1, article 5, 2014. View at Publisher · View at Google Scholar
  158. K. Kojima, A. Takata, C. Vadnais et al., “MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma,” Nature Communications, vol. 2, article 338, 2011. View at Publisher · View at Google Scholar
  159. J. Hou, L. Lin, W. Zhou et al., “Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma,” Cancer Cell, vol. 19, no. 2, pp. 232–243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  160. R. Nagashio, E. Arai, H. Ojima, T. Kosuge, Y. Kondo, and Y. Kanai, “Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage,” International Journal of Cancer, vol. 129, no. 5, pp. 1170–1179, 2011. View at Publisher · View at Google Scholar · View at Scopus
  161. M.-H. Teiten, M. Dicato, and M. Diederich, “Curcumin as a regulator of epigenetic events,” Molecular Nutrition and Food Research, vol. 57, no. 9, pp. 1619–1629, 2013. View at Publisher · View at Google Scholar · View at Scopus
  162. A. S. Darvesh and A. Bishayee, “Chemopreventive and therapeutic potential of tea polyphenols in hepatocellular cancer,” Nutrition and Cancer, vol. 65, no. 3, pp. 329–344, 2013. View at Publisher · View at Google Scholar · View at Scopus
  163. W. J. Lee and B. T. Zhu, “Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols,” Carcinogenesis, vol. 27, no. 2, pp. 269–277, 2006. View at Publisher · View at Google Scholar · View at Scopus
  164. K. S. Furtado, J. Polletini, M. C. Dias, M. A. M. Rodrigues, and L. F. Barbisan, “Prevention of rat liver fibrosis and carcinogenesis by coffee and caffeine,” Food and Chemical Toxicology, vol. 64, pp. 20–26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  165. C. Verslype, “Interfering with epigenetics in hepatocellular carcinoma: out of the shelter?” Journal of Hepatology, vol. 65, no. 2, pp. 243–244, 2016. View at Publisher · View at Google Scholar · View at Scopus
  166. A. Bishayee and N. Dhir, “Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis,” Chemico-Biological Interactions, vol. 179, no. 2-3, pp. 131–144, 2009. View at Publisher · View at Google Scholar · View at Scopus
  167. A. Bishayee, A. Waghray, K. F. Barnes et al., “Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis,” Pharmaceutical Research, vol. 27, no. 6, pp. 1080–1091, 2010. View at Publisher · View at Google Scholar · View at Scopus
  168. A. Bishayee, T. Politis, and A. S. Darvesh, “Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma,” Cancer Treatment Reviews, vol. 36, no. 1, pp. 43–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  169. H.-G. Wang, X.-D. Huang, P. Shen, L.-R. Li, H.-T. Xue, and G.-Z. Ji, “Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro,” International Journal of Molecular Medicine, vol. 31, no. 4, pp. 967–974, 2013. View at Publisher · View at Google Scholar · View at Scopus
  170. J. D. Clarke, R. H. Dashwood, and E. Ho, “Multi-targeted prevention of cancer by sulforaphane,” Cancer Letters, vol. 269, no. 2, pp. 291–304, 2008. View at Publisher · View at Google Scholar · View at Scopus
  171. M. Mottamal, S. Zheng, T. L. Huang, and G. Wang, “Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents,” Molecules, vol. 20, no. 3, pp. 3898–3941, 2015. View at Publisher · View at Google Scholar · View at Scopus
  172. R. Buurman, E. Grlevik, V. Schffer et al., “Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells,” Gastroenterology, vol. 143, no. 3, pp. 811–820.e15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  173. S. Armeanu, A. Pathil, S. Venturelli et al., “Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357,” Journal of Hepatology, vol. 42, no. 2, pp. 210–217, 2005. View at Publisher · View at Google Scholar · View at Scopus
  174. A. Pathil, S. Armeanu, S. Venturelli et al., “HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL,” Hepatology, vol. 43, no. 3, pp. 425–434, 2006. View at Publisher · View at Google Scholar · View at Scopus
  175. Z. S. Guo, J. A. Hong, K. R. Irvine et al., “De novo induction of a cancer/testis antigen by 5-aza-2′- deoxycytidine augments adoptive immunotherapy in a murine tumor model,” Cancer Research, vol. 66, no. 2, pp. 1105–1113, 2006. View at Publisher · View at Google Scholar · View at Scopus